UBS launches loan product
UBS has launched a new product – a limited recourse loan with no margin calls.
The company launched the product, UBS Investment Builders, this week claiming it would investors the ability to purchase shares, exchange traded funds (ETFs) and listed managed funds by paying a portion of the underlying security price themselves, while UBS then provided a limited recourse loan for the balance of the purchase price.
It said a key feature of buying the underlying shares through UBS Investment Builders was that investors became the beneficial owner and received exposure to price performance, dividends and potential franking credits.
The company claimed superannuation funds would be able to use UBS Investment Builders as one of the few ways to borrow to invest in listed shares and ETFs.
Commenting on the product, UBS head of derivative sales, Travis Miller said the product was innovative because it combined a limited recourse loan with a share or ETF that could be purchased on the ASX in a similar way to buying shares outright.
"UBS Investment Builders also offer individuals and SMSFs the benefits of potential interest deductions and franking credits, and in the case of UBS Dividend Builders, access to potentially enhanced dividend income streams,” he said.
Recommended for you
As advisers risk losing two-thirds of FUA during the $3.5 trillion wealth transfer, two co-founders underscore why fostering trust with the next generation is vital to retaining intergenerational wealth.
As advisers seek greater insights into FSCP determinations, what are the various options considered by the panel and can a decision be appealed?
Amid the current financial adviser shortage, advice firm Link Wealth is looking to expand its financial literacy program for high school students across the country.
TAL Risk Academy has updated its range of ethics courses to help financial advisers meet their CPD requirements following adviser feedback, including interpreting FSCP determinations.
